IMPORTANT NOTES

• Abstracts can only be submitted online. In response to feedback, we will no longer use the downloadable template but will move to a fully online submission system where you can submit your work directly in the portal. 
• We discourage splitting data from one study into several abstracts (“salami-slicing”) unless the amount of data cannot be condensed into a single abstract. In the submission forms, authors must indicate whether there are several abstracts related to a single study. The Congress Committee will review abstracts for salami-slicing, and this may be a cause for rejection, if not indicated on the submission form.
• Submitters will have to choose a topic, as well as a sub-topic. Sub-topics categorise the abstract as either 'adult rheumatology' or 'paediatric rheumatology'.
• Abstracts should not be submitted if the following applies:
• • may not have been or will not be published in a print or online journal before the EULAR abstract submission deadline, 15 January 2026 (excluding publication of abstracts presented at previous conferences in conference proceedings or similar). Publication of data as an article in a print or an online scientific journal after the submission deadline is not a violation of the embargo;
  • may not have been presented before the EULAR 2025 Congress;
  • may not have been presented between the EULAR 2025 Congress and the week of outcome notifications for the EULAR 2026 Congress, unless disclosed in the submission;
• Abstracts accepted for the congress are subject to the EULAR Embargo rules. With the submission of an abstract, the authors agree to the embargo rules.
• The inclusion of trade names/brand names is not allowed in the abstract, including statistical programmes or other, unless this is peculiar and adds value to their work. The mentioning of agents/molecules must follow the scientific standard for publications.
• For clinical abstract submissions, the presenting author can be any of the listed authors without affiliations to industry. For basic, translational and clinical studies below Phase 2, the presenting author can be any of the listed authors.
• Conflict of interest: It is the intent of EULAR to provide high quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during the abstracts' submission.
• Russian and Belarusian submissions
• • EULAR will not accept any submission from Russian companies. Note: This does not include university institutions but rather focuses on Russian pharmaceutical, biotech, or other similar industry bodies.
  • EULAR will not accept any abstract for which the presenter is a co-author based at a Russian or Belarusian institution, even if from a non-industry institution.
  • EULAR will allow submissions from internationally collaborative authors, including authors from Russian or Belarusian institutions, assuming the above criteria are not breached.

REVIEW

• Abstracts are reviewed blindly. The reviewers will judge the abstracts according to the scientific or clinical value, relevance to EULAR, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.
• In order to better capture instances of salami-slicing, and to be fair to all authors who submit their work in accordance with EULAR guidelines, including those who declare multiple submissions, we will use analysis software to detect potentially similar abstracts. A report will be created from this analysis which will highlight submissions with potential overlap, which will be given to the Congress Committee for review. Those deemed guilty of salami-slicing will be rejected.
• Abstract acceptance will be in one of four categories:
  • Oral presentation
  • Poster tour presentation
  • Poster view
  • Publication only (no presentation at the Congress, but published in the EULAR Abstract Book).
• Licence agreement: The authors, represented by the presenting author, will have to sign an agreement to grant EULAR the right to use the entire presentation (slides, video and audio recording during the conference) during the congress and subsequently for (paid or unpaid) educational purposes.
• Abstracts not adhering to these guidelines will be rejected. If you do not agree with any of these rules, you should not submit an abstract. The final decision regarding acceptance of an abstract will be taken by the EULAR Scientific Programme Committee. EULAR does not communicate, nor enter into correspondence on the reasons for acceptance or rejection of an abstract.

ACCEPTANCE

• Notifications of outcomes will be released in the week of 16 March 2026.
• Accepted abstracts will be published in a supplement to the Annals of Rheumatic Diseases (ARD). Information on accepted abstracts (title and presenting author) is available in the online programme. Abstracts will be published in the EULAR Abstract Archive approximately three weeks prior to the congress.
• Abstract outcomes will be communicated via your account, where you can find all information pertaining to the status of your abstract as well as information about the associated presentation, if selected. 
• Case reports will not be added in the ARD and will only be available in the EULAR Abstract Archive.
• The submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session and the time assigned by the EULAR Scientific Programme Committee. We therefore recommend submitters of abstracts to register for the congress at the time of abstract submission.
• If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to the abstract helpdesk at congress.abs@eular.org.

TRAVEL

• Please note that the presenting authors of all accepted abstracts for oral, poster tour and poster view presentations will be required to present physically in London. 
• Failure to be onsite at the assigned day and time of presentation will result with abstract being completely removed from the EULAR Abstract Archive and Abstract Book.
• • If, unexpectedly, the presenting author is unable to attend the congress, they would need to assign a co-author to present the abstract onsite. If a replacement author is not provided, the work may be removed from the Abstract Archive and Abstract Book. 
• If the presenting author needs a letter of invitation for their visa application, they can apply for this via EULAR congress account once they have completed their congress registration. The registration team will provide them with the letter once requested. If the registration is being organised by a third party, they can request a visa letter of invitation on behalf of the presenting author.

FAQS

If you have any questions regarding the abstract submission that we haven't answered here, please check our Help Centre for detailed information, or submit a query if further help is needed.